Lung cancer genetic test: What it detects and who needs it

A lung cancer genetic test is a laboratory analysis of cancer cells or blood that identifies the gene mutations driving tumor growth.

NCCN and ASCO guidelines both call for comprehensive biomarker testing in every patient with non-small cell lung cancer (NSCLC) at diagnosis. Without those results, the oncology team chooses treatment blind while a matched targeted drug may already exist. This guide covers what the test detects, who needs it, how the sample is collected, and how practices keep testing on schedule.

Found our content helpful?

Key takeaways

A lung cancer genetic test reads tumor DNA for actionable mutations that guide targeted therapy, which is a separate job from inherited risk testing.

Every patient with NSCLC needs comprehensive biomarker testing at diagnosis, covering EGFR, ALK, ROS1, KRAS G12C, PD-L1 and six further markers.

Somatic testing reads the tumor’s acquired mutations and guides treatment. Germline testing reads inherited DNA and informs family risk.

A negative liquid biopsy does not rule out an actionable mutation, so tissue sequencing stays the reference standard.

Practice management software like Pabau tracks specimen status, turnaround times and result delivery in the same system as the chart.

What is a lung cancer genetic test?

A lung cancer genetic test is a molecular analysis that looks for mutations, fusions, or other alterations in the DNA of cancer cells. It can also read circulating tumor DNA carried in the blood. These alterations drive the cancer’s growth, so identifying them tells an oncologist which targeted drugs have a chance of working.

Two different test types share the same name, and the distinction matters clinically:

• Somatic testing looks at the tumor itself. The mutations found are acquired rather than inherited, and they guide treatment decisions.
• Germline testing looks at inherited mutations present in every cell. It informs hereditary cancer risk for the patient and their family, not treatment selection.

Most patients with lung cancer need somatic testing. Germline testing is recommended in specific circumstances, such as a strong family history or a never-smoker presentation in a young patient.

Somatic versus germline testing: What is the difference?

Somatic testing analyzes the tumor’s acquired mutations, while germline testing looks at inherited DNA present from birth. The table below shows the key differences at a glance.

A positive EGFR result on somatic testing does not mean the patient carries a germline EGFR variant. Almost every EGFR mutation found in a lung tumor is acquired. A germline EGFR T790M variant has been described in families with hereditary lung cancer, but confirming it takes separate germline testing.

Who needs a lung cancer genetic test?

Every patient newly diagnosed with NSCLC should have comprehensive biomarker testing, regardless of stage, smoking history, or histology. This is the recommendation from the National Comprehensive Cancer Network (NCCN) and ASCO. Stage IV patients have the most urgent need because treatment decisions are immediate. Stage I to III patients benefit too, because mutation data informs adjuvant therapy choices and surveillance planning.

Germline testing is appropriate when any of the following apply:

• Never-smoker or light-former-smoker younger than 50
• Multiple first-degree relatives with lung cancer
• Personal or family history of another hereditary cancer syndrome (Li-Fraumeni, Lynch)
• Somatic result showing a mutation pattern suggestive of inherited origin

Small cell lung cancer (SCLC) does not routinely benefit from biomarker-directed targeted therapy, though PD-L1 testing is sometimes performed. Check the current NCCN guidelines before ordering for SCLC, because the evidence base is still moving.

What the test detects: The standard biomarker panel

Comprehensive biomarker testing covers point mutations, gene fusions, insertions and deletions, amplifications, and protein expression. The table below maps the standard markers to their alteration type and therapy options. It follows Lung Cancer Research Foundation guidance and verified FDA approvals.

PD-L1 is not a targetable oncogene in the same sense. It predicts immunotherapy response rather than directing a small-molecule drug. EGFR-mutated tumors should generally not receive first-line immunotherapy alone even when PD-L1 is highly expressed, because targeted therapy performs better.

Grouped by the kind of alteration involved, the panel makes the assay requirement clearer, and it shows how much of the panel is currently actionable.

How the sample is collected: Tissue biopsy vs liquid biopsy

Two sample collection methods support lung cancer genetic testing. Tissue biopsy remains the reference standard, and liquid biopsy is the alternative when tissue is insufficient or repeat testing is needed.

• Tissue biopsy: A sample of the tumor from bronchoscopy, CT-guided biopsy, or surgical resection goes for next-generation sequencing. This gives the most complete mutational profile. Re-biopsy at progression is sometimes needed to detect resistance mutations such as EGFR T790M.
• Liquid biopsy (ctDNA): A blood draw captures circulating tumor DNA shed by cancer cells. Turnaround is faster and it avoids procedural risk. Use it when tumor tissue is insufficient, the biopsy site is inaccessible, or rapid reassessment is needed at progression. Sensitivity is lower than tissue NGS, so a negative result does not rule out an actionable mutation.

Whichever route the sample takes, someone has to know where it is. Pabau’s lab management software logs specimen status, flags pending results, and tracks turnaround inside the same system used for scheduling and clinical notes.

What is next-generation sequencing (NGS) in lung cancer?

Next-generation sequencing (NGS) is the recommended approach for comprehensive biomarker testing because it analyzes hundreds of genes at once from a single tumor specimen. Sequential single-gene testing takes longer, uses more tissue, and risks running out of sample before all relevant markers are assessed.

NGS panels such as FoundationOne CDx and Guardant360 detect point mutations, fusions, insertions, deletions, copy number alterations, and tumor mutational burden (TMB) in one run. NCCN and ASCO both recommend NGS as the preferred method for NSCLC biomarker testing.

What the three result categories mean

Results fall into three broad categories, each with a different clinical implication.

• Actionable mutation identified: A driver mutation with an FDA-approved targeted therapy is present, and the oncologist selects the matching drug. This is where biomarker testing delivers its clearest value.
• No actionable mutation identified (driver-negative): Targeted therapy is not indicated. Treatment shifts to immunotherapy guided by PD-L1 expression, chemotherapy, or a combination regimen. The absence of a driver mutation is itself a clinically meaningful result.
• Variant of unknown significance (VUS): A mutation is detected but its clinical relevance is unclear. A VUS is not currently actionable and should not drive treatment decisions. It may be reclassified as evidence accumulates.

Results should always be discussed in a multidisciplinary team (MDT) setting, not in isolation. Oncologist, pathologist, and, where relevant, genetic counselor input shapes the final treatment recommendation.

Inherited risk: Hereditary panels and germline testing

Most lung cancer is not hereditary, but a subset of patients carry germline variants that raise their risk. Hereditary panels test genes including STK11, associated with Peutz-Jeghers syndrome, TP53, associated with Li-Fraumeni syndrome, and germline EGFR T790M in rare families.

The American Cancer Society’s guidance on genetic testing for cancer risk sets out when germline testing is appropriate. It also covers what the results mean for patients and their relatives. Key considerations:

• A positive germline result may prompt surveillance recommendations for first-degree relatives
• Insurability and psychological implications should be discussed before testing
• Hereditary lung cancer syndromes are uncommon, so do not overstate prevalence when counseling patients
• Germline testing requires a separate consent process from somatic tumor testing

The role of genetic counseling

Genetic counseling is recommended before and after germline testing, as ASCO guidelines and the National Cancer Institute’s genetic testing fact sheet both set out. Somatic testing does not usually require counseling, though a clinical genetics referral may be appropriate when somatic results suggest a possible germline origin.

That conversation needs a record. A structured medical consent form captures what was explained, what the patient agreed to, and who was present. That record matters most when germline implications are raised for the first time.

What a genetic counseling session typically covers:

• Review of personal and family cancer history
• Explanation of what the test can and cannot tell the patient
• Discussion of possible results and their implications for treatment and family members
• Psychosocial assessment and support planning
• Consent documentation

Access to certified genetic counselors (CGCs) varies by geography and institution. Telehealth genetic counseling is increasingly available and suits most pre- and post-test discussions.

How Pabau keeps biomarker testing on schedule

Coordination is where biomarker testing usually loses days. Specimen ordering, lab liaison, turnaround tracking, result receipt and patient notification each add a handoff, and every handoff can push the treatment start date back. Reflex biomarker ordering belongs inside the diagnostic pathway rather than sitting beside it as a separate administrative task.

Practices that standardize this see fewer specimens sent without adequate tissue and fewer patients lost between diagnosis and the results discussion. The workflow changes that make the difference are specific:

• Reflex ordering protocols: Agree who orders biomarker testing, and at what point in the diagnostic pathway. Take the decision out of ad hoc clinical judgment.
• Specimen tracking: Know which patients have samples in transit, which are awaiting sequencing, and which have reports ready.
• Result notification: Trigger an alert when a report arrives, routed to the responsible clinician. Pabau’s automated workflows can book the recall appointment at the same time.
• Documented consent: Keep the pre-test conversation and the signed form in the chart, where patient intake software can hold both without paper.
• MDT scheduling: Put tumor board meetings in the practice calendar ahead of time, so a result can move to discussion without waiting for a slot.

Pabau, our practice management platform, holds all of that in one place. The patient records system stores the test result, the MDT discussion, and the reasoning behind each treatment decision. The next clinician reading the chart can see why the plan was chosen.

Keep every pending lab result in one place

Pabau lets oncology and respiratory practices log lab orders, track specimen turnaround, trigger follow-up when a report lands, and keep clinical records together. See how it handles a biomarker testing pathway.

Book a demo

Conclusion

Biomarker testing is now part of the NSCLC diagnosis itself, not an optional extra ordered later. The practical question has moved from whether to test to how fast the result gets back and who acts on it.

Two decisions carry most of the weight. Choose the sample route deliberately, remembering that a negative liquid biopsy still leaves tissue sequencing on the table. And agree in advance who orders the panel, so testing never waits on a conversation between specialties.

Pabau’s lab management and automated recall features track specimens, receive results, and trigger patient follow-up in one system. Book a demo to see how it handles a complex diagnostic pathway end to end.

Continue your research

Documenting an oncology care plan alongside the test result? Cancer nursing care plan sets out the assessments, interventions and review points worth recording.

Need to put a confirmed diagnosis in writing for a patient or employer? Diagnosis letter from a doctor shows what belongs in the letter and what to leave out.

Still tracking consent and results across paper and email? Clinical documentation software compares what the main systems do with structured records.

Frequently asked questions